Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 7.13B 6.38B 5.9B 5.34B 10B 679B 10.17B 71.02B 28.09B 355B 26.78B 26.2B 1,124B P/E 2026 *
-12.2x
P/E 2027 * -22.3x
Enterprise Value 7.03B 6.29B 5.82B 5.27B 9.86B 669B 10.02B 70B 27.69B 350B 26.39B 25.83B 1,108B EV / Sales 2026 *
7.62x
EV / Sales 2027 * 5.3x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.14%
1 week+1.12%
Current month-2.75%
1 month-2.43%
3 months-23.22%
6 months-40.74%
Current year-45.11%
1 week 42.58
Extreme 42.58
45.76
1 month 42.08
Extreme 42.08
46.94
Current year 42.08
Extreme 42.08
86.74
1 year 42.08
Extreme 42.08
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 30/06/2012
Chief Executive Officer 64 31/12/2019
Director of Finance/CFO 64 30/04/2000
Director TitleAgeSince
Director/Board Member 64 12/12/2005
Director/Board Member 73 30/04/2002
Director/Board Member 64 24/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Others

Chief Technology Officer

110 0.0001%
31/08/26 Others

Executive/Senior Manager

58 0.0000%
31/08/26 Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.14%+1.12%-38.72%-2.14% 7.13B
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+7.23%+11.14%+74.78% 54.78B
+0.47%+5.10%+8.22%+101.52% 53.49B
-2.06%+2.51%+24.07%+50.98% 45.98B
-1.79%+0.49%+19.32%+122.77% 42.94B
-1.65%+3.34%+237.56%+819.04% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+18.47%+55.14%+45.58% 23.67B
Average +0.68%+2.00%+39.93%+133.31% 39.02B
Weighted average by Cap. +0.14%+2.54%+44.38%+147.10%

Financials

2026 *2027 *
Net sales 922M 825M 763M 691M 1.29B 87.76B 1.31B 9.18B 3.63B 45.9B 3.46B 3.39B 145B 1.36B 1.22B 1.13B 1.02B 1.91B 129B 1.94B 13.54B 5.36B 67.67B 5.1B 4.99B 214B
Net income -579M -518M -479M -434M -812M -55.12B -826M -5.77B -2.28B -28.83B -2.17B -2.13B -91.28B -327M -293M -271M -245M -459M -31.14B -466M -3.26B -1.29B -16.29B -1.23B -1.2B -51.58B
Net Debt -103M -92.09M -85.2M -77.14M -144M -9.8B -147M -1.03B -406M -5.12B -387M -378M -16.23B 68.31M 61.08M 56.51M 51.17M 95.76M 6.5B 97.33M 680M 269M 3.4B 256M 251M 10.76B
Projected Income Statement - Annual - Ionis Pharmaceuticals, Inc.
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
26/10/26 US$43.42 +1.14% 3,197,333
23/10/26 US$42.93 -2.23% 3,015,008
22/10/26 US$43.91 -0.81% 5,012,019
21/10/26 US$44.27 -2.49% 2,269,836
20/10/26 US$45.40 +2.30% 2,487,410
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Ionis Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
42.93USD
Average target price
84.13USD
Spread / Average Target
+95.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ionis Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IONS Stock